구조모아 (StructureMoa)항암 chemical structure spider web
방문Fundamenta TherapeuticsLtd.
Chimeric Antigen Receptor T-cells(Fundamenta Therapeutics, Ltd.)은 Platinum-Resistant Ovarian Carcinoma 표적 세포·유전자 치료로, Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) 영역에서 개발·상용화 중입니다. 작용기전: CAR-T and BsAb therapy, as an independent and alternative niche. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Platinum-Resistant Ovarian Carcinoma
Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML)
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
bispecific antibody duopoly: ex vivo armed T cells for solid tumors
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized scFvs, hinge/TM optimization, and ITAM calibration have been developed, along with programmable "sw
unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs
CAR-T and BsAb therapy, as an independent and alternative niche
cytokine release syndrome
Biomarker potential and therapeutic targeting to counteract drug resistance
escape via heterogeneity and target antigen loss, and treatment-related toxicities like cytokine release syndrome
구조화 데이터
xenograft mouse
mouse, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Fundamenta TherapeuticsLtd.
Chimeric Antigen Receptor T-cells(Fundamenta Therapeutics, Ltd.)은 Platinum-Resistant Ovarian Carcinoma 표적 세포·유전자 치료로, Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) 영역에서 개발·상용화 중입니다. 작용기전: CAR-T and BsAb therapy, as an independent and alternative niche. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Platinum-Resistant Ovarian Carcinoma
Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML)
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
bispecific antibody duopoly: ex vivo armed T cells for solid tumors
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized scFvs, hinge/TM optimization, and ITAM calibration have been developed, along with programmable "sw
unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs
CAR-T and BsAb therapy, as an independent and alternative niche
cytokine release syndrome
Biomarker potential and therapeutic targeting to counteract drug resistance
escape via heterogeneity and target antigen loss, and treatment-related toxicities like cytokine release syndrome
구조화 데이터
xenograft mouse
mouse, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.